NPI registry status
Active
2026 NPPES data Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician NPI 1558756866 D.O.
Verify on CMS → Tara Marczak, D.O.
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician in Burlington, Massachusetts.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 621 in Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
903
Medicare Part D claims · 255 beneficiaries · Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician avg: 661
Generic prescribing
75%
generic claims · 25% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$312.22
6 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Tara Marczak, D.O. filed 903 Medicare Part D claims in 2024 as a Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician in Burlington, Massachusetts, prescribing 75% generic.
- 903
- Part D claims, 2024
- 75%
- generic prescribing
- Likely
- board-certified (heuristic)
- ≥74th
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Tara Marczak, D.O.
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1558756866), first enumerated 04/02/2015.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 903 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- Reported
Industry payment transparency
$312.22 in reported industry payments (6 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- State context
State board disciplinary context
Massachusetts statewide board action statistics are published annually — these figures describe aggregate state activity, not Tara Marczak, D.O.'s individual license status. Verify directly with the state medical board.
Source: BORIM annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1558756866 · Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician
NPI-10 · ENUM-MID · TAX-NARROW · RX-LIGHT · BOOK-THIN · PHOTO-ENUM
- NPI-10 1558756866
- ENUM-MID 2015
- TAX-NARROW 621
- RX-LIGHT 903
- BOOK-THIN 21 in Massachusetts
- PHOTO-ENUM Amy Askew · 2015
Tara Marczak, D.O.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
903 ≥ 74th percentile 74% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
✓
Board certification likely (heuristic, not verified)
Tara Marczak, D.O. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Tara Marczak, D.O.?
Quality data not reportedPrimary specialty
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician
Medicare Part D claims
903 37% vs specialty avg
Specialty distribution in Massachusetts
How Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician compares to other specialties among Massachusetts providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1558756866 |
|---|---|
| Specialty | Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician |
| Credentials | D.O. |
| Gender | Female |
| NPI Issued | 04/02/2015 |
Hospital and facility affiliations
Facilities where Tara Marczak, D.O. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Atrius Health Inc
Burlington, MA
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Tara Marczak, D.O.. Source: openpaymentsdata.cms.gov.
Total received
$312
Largest payer
Axonics, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - Massachusetts BORIM 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~38K Massachusetts medical licensees in 2023 - they are NOT specific to Tara Marczak, D.O.. To verify Tara Marczak, D.O.'s current license status, search the BORIM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
80
Total board actions, Massachusetts 2023
Across 78 cases
2.11
Actions per 1,000 licensees
Massachusetts statewide rate
probation
Most common action type
29 cases
BORIM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Massachusetts disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
Tara Marczak, D.O. - brand share 25.0%
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician average
25% brand-name claims vs 75% generic, on 903 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
903
Total Claims
$189K
Total Drug Cost
255
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,506
- Total Day Supply
- 38,414
- Brand vs Generic
- 25% brand / 75% generic
- Brand Drug Cost
- $140K
- Generic Drug Cost
- $50K
- Opioid Claims
- 27 (3.0% rate)
- Antibiotic Claims
- 240
Patient Demographics
- Average Patient Age
- 74.6 years
- Avg HCC Risk Score
- 1.10
- Gender Split
- 100% female / 0% male
- Age Distribution
- <65: 13, 65-74: 116, 75-84: 99, 85+: 27
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Tara Marczak, D.O. prescribes most
Top Medicare Part D drugs by claim count, 2024
- Estradiol
Estradiol
222 claims
- Gemtesa
Gemtesa
117 claims
- Myrbetriq
Myrbetriq
89 claims
- Cephalexin 83
Cephalexin
83 claims
- Nitrofurantoin Mon… 71
Nitrofurantoin Mono-Macro
71 claims
- Mirabegron Er 55
Mirabegron Er
55 claims
- Oxycodone Hcl 27
Oxycodone Hcl
27 claims
- Fluconazole 25
Fluconazole
25 claims
| Drug | Claims |
|---|---|
| Estradiol | 222 |
| Gemtesa Vibegron | 117 |
| Myrbetriq Mirabegron | 89 |
| Cephalexin | 83 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 71 |
| Mirabegron Er Mirabegron | 55 |
| Oxycodone Hcl | 27 |
| Fluconazole | 25 |
| Trospium Chloride | 24 |
| Ciprofloxacin Hcl | 23 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician in MA →
All providers in Massachusetts →
Compare specialties →
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician Overview
How Tara Marczak, D.O. fits within the Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician landscape nationally.
621
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician Providers in US
50
States with Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician
661
Avg Claims per Provider
Tara Marczak, D.O.'s 903 claims are above the specialty average of 661.
Nationwide Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Marczak, both outside Massachusetts so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2015)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician Providers in Massachusetts
Other clinicians with the same primary specialty enrolled in Massachusetts, drawn from the same CMS NPPES roster as Marczak.
One of 21 Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician providers enrolled in Massachusetts, 5 are shown here.
Frequently Asked Questions
What is Tara Marczak, D.O.'s specialty? ▼
Tara Marczak, D.O. specializes in Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician and practices in Burlington, Massachusetts. Credentials: D.O..
How much does Tara Marczak, D.O. prescribe under Medicare Part D? ▼
In 2024, Tara Marczak, D.O. wrote 903 Medicare Part D claims totaling $189K in drug costs for 255 beneficiaries.
Where is Tara Marczak, D.O. located? ▼
Tara Marczak, D.O. is located at 20 WALL ST, Burlington, MA, 01803. Phone: (781) 221-2940.
What is Tara Marczak, D.O.'s NPI number? ▼
Tara Marczak, D.O.'s National Provider Identifier (NPI) is 1558756866, issued on 04/02/2015.
Does Tara Marczak, D.O. prescribe more brand-name or generic drugs? ▼
Tara Marczak, D.O.'s prescribing is 25% brand-name and 75% generic drugs by claim count, with $140K in brand drug costs.
Does Tara Marczak, D.O. prescribe opioids? ▼
Yes, Tara Marczak, D.O. had 27 opioid claims in 2024 with an opioid prescribing rate of 3.0%.
How many Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician providers are there in the US? ▼
There are 621 Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician providers across 50 states in the US. The average Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician provider writes 661 Medicare Part D claims per year.
What drugs does Tara Marczak, D.O. prescribe most often? ▼
Based on 2024 Medicare Part D data, Tara Marczak, D.O.'s most frequently prescribed drugs include Estradiol, Gemtesa, Myrbetriq. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Tara Marczak, D.O. accept Medicare? ▼
Tara Marczak, D.O. appears in CMS Medicare data with 903 Part D claims and 255 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Tara Marczak, D.O.'s credentials? ▼
Tara Marczak, D.O.'s NPI is 1558756866 with credentials D.O.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.